Enliven Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Enliven Therapeutics Inc 's ROA in the second quarter of 2026?
Enliven Therapeutics Inc recorded a cumulative net loss of $-106 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -13.66%.

However, within the Healthcare sector 348 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3461, from total ROA ranking in the first quarter of 2026 at 4141.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	231.41 %	53.63 %	46.25 %	60.72 %	54.07 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-106	-99	-104	-97	-100
Return On Assets (TTM)	-13.66 %	-20.41 %	-23.39 %	-23.96 %	-27.89 %
ELVN's Total Ranking	# 3461	# 4141	# 3630	# 3747	# 3849
Total Assets (TTM) in million	1,670	465	476	491	504
Seq. Total Assets Change	259.24 %	-2.38 %	-3 %	-2.58 %	66.54 %
Seq. Net Income Change	-	-	-	-	-

ELVN's 5 Years Annual ROA >> Back to ELVN Management Effectiveness >> Compare ELVN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 126
Sector	# 349
Overall	# 3387

Return On Assets Statistics
High	Average	Low
5.64 %	-36.69 %	-163.34 %
(Dec 31 2022)		(Sep 30 2012)

News about Enliven Therapeutics Inc Return on Assets ROA

Navigating Promising Clinical Trials Amid Financial Challenges A Close Look at Enliven Therapeutics

Enliven Therapeutics has garnered attention in the biopharmaceutical landscape with the recent announcement of positive updates from its Phase 1 clinical trial for ELVN-001, a promising therapeutic candidate aimed at treating Chronic Myeloid Leukemia (CML). This information was presented at the 26th Annual John Goldman Conference, ESH-iCMLf, showcasing the potential efficacy of ELVN-001, which is being closely monitored by both clinical experts and investors alike. Positive Phase 1 Clinical Trial DataThe data update from Enliven Therapeutics highlighted encouraging results that suggest ELVN-001 may effectively address the unmet medical needs of patients suffering from CML. As a condition characterized by an overproduction of myeloid cells in the bone marrow, CML can lead to severe complications if not properly managed. With ELVN-001 s promising results, there is hope for a new treatment avenue that could offer patients better outcomes and improved quality of life.

Financial Statements
Enliven Therapeutics Inc 's Assets	$ 1,670 million	ELVN's Balance sheet
Enliven Therapeutics Inc 's Income	$ -32 million	Quarterly ELVN's Income Statement
ELVN's Income by Division		See ELVN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	46.25 %	19.76 %	196.68 %	-2.15 %	3.09 %
Total Assets in million	476	326	272	92	94
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-104	-89	-72	1	-43
Annual Return On Assets	-21.78 %	-27.34 %	-26.33 %	1.62 %	-46.43 %

ELVN's 5 Years Annual ROA >> Back to ELVN Management Effectiveness >> Compare ELVN ROA to its Competitors

More Return On Assets Ratios
ELVN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ELVN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ELVN's Competitors
Subscribers only: Roa for Enliven Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ELVN's Customers

You may also want to know
ELVN's Roi	ELVN's Inventory Turnover Ratio	ELVN's Growth Rates	ELVN's Dividend Comparisons
	ELVN's Profitability Ratios	ELVN's Asset Turnover Ratio	ELVN's Dividend Growth
ELVN's Roe	ELVN's Valuation Ratios	ELVN's Financial Strength Ratios	ELVN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-10T13:15:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.